Dense Breasts and Supplemental Screening: What the National Notification Rule Does and Does Not Prove

Dense Breasts and Supplemental Screening: What the National Notification Rule Does and Does Not Prove#

If you have had a mammogram since September 10, 2024, your report told you one new thing: whether your breast tissue is "dense." That single line is now federal law, and it is easy to read more into it than it says. The notice standardizes what you are told. It does not prove that adding an ultrasound or an MRI will help you live longer.

Key points#

• A U.S. rule now requires every mammography facility to report breast density in plain language, in two buckets: "dense" or "not dense."
• Dense tissue does two things at once: it can hide cancers on a mammogram, and it is itself a modest risk factor for breast cancer.
• Supplemental ultrasound and MRI find extra cancers, but finding more cancers is not the same as preventing more deaths.
• The strongest trial evidence (the DENSE study) applies to MRI in women with extremely dense tissue and measured fewer between-screen cancers, not fewer deaths.
• The notice is a prompt for a conversation, not a prescription for a test.

What changed, and why it is worth understanding#

For years, whether a patient learned about her breast density depended on which state she lived in. Some states mandated detailed notification, some said nothing, and the wording varied from one law to the next. The FDA's final rule amending the Mammography Quality Standards Act replaced that patchwork with one national standard. It was published in March 2023 and became enforceable on September 10, 2024.

Radiologists have long sorted density into four BI-RADS levels, from almost entirely fatty, through scattered fibroglandular tissue, to heterogeneously dense, and finally extremely dense. The rule folds those four grades into two categories that patients actually see. The lower two are reported as "not dense." The upper two are reported as "dense." For anyone in the dense group, the report must add a fixed sentence noting that, in some people with dense tissue, other imaging in addition to a mammogram may help find cancers, and it points the reader to a clinician.

Two things about that mandated text are easy to miss. The language is standardized, so a facility cannot make it sound more alarming or more reassuring than the rule intends. And it is deliberately hedged. It says supplemental imaging "may help," it names no particular test, and it recommends nothing. As a 2023 review in the Journal of Breast Imaging by Berg and colleagues describes, the standard exists to make notification uniform, not to hand patients a screening plan.

The two truths packed into the word "dense"#

A density notice is really telling you two separate facts. First, dense tissue is harder to see through. On a mammogram, both dense tissue and tumors appear white, so a cancer can blend into the background the way a snowball blends into a snowbank. Second, having dense tissue is itself a modest, real risk factor for developing breast cancer, separate from the masking problem.

Because these two truths travel together under one label, it is tempting to treat the notice as a verdict on personal risk. It is not. Roughly half of women screened fall into the dense category, which means the label sorts an enormous population using a threshold that is genuinely fuzzy at the boundary. Where "scattered" ends and "heterogeneously dense" begins is a visual judgment, and the same images read by two radiologists, or by one radiologist on two different days, do not always land in the same bucket. Density can also shift over time with age, weight, and hormonal changes. The notice reports a category from one reading on one day, not a fixed trait.

Density is also only one strand of risk. Family history, inherited variants such as BRCA, prior high-risk biopsies, and validated lifetime-risk calculators each carry weight of their own. A woman with extremely dense tissue and no other risk factors and a woman with average density who carries a BRCA mutation are in very different situations, even though only the first receives the density flag. The rule surfaces one variable. It does not compute your risk.

The gap between finding cancer and saving lives#

Here is where careful reading matters most. The best-supported claim for supplemental screening is that it finds more cancers, and that claim is true. The Journal of Breast Imaging review summarizes that adding ultrasound turns up roughly two to three extra cancers per 1,000 examinations, while MRI finds on the order of ten to twenty per 1,000 on a first round and fewer on later rounds, with contrast-enhanced mammography landing in a similar range. Each of these also produces more false alarms and more benign biopsies, especially the first time it is done.

Finding more cancers, though, is not the same as preventing more deaths. Extra detection can inflate the count in two ways that do not change how long a person lives. One is lead time: a cancer found a bit earlier, with the eventual outcome unchanged. The other is overdiagnosis, the detection of small, slow lesions, such as some cases of ductal carcinoma in situ, that might never have caused harm. A screening test proves its worth by pushing late-stage disease and death rates down, not by adding to a tally of findings. That distinction is exactly what a density notice cannot resolve.

What the trials actually show#

The firmest evidence comes from the DENSE trial, a randomized study published in the New England Journal of Medicine in 2019 in women with extremely dense breasts. Offering those women supplemental MRI cut the rate of interval cancers, the ones that surface between scheduled mammograms, from about 5.0 to 2.5 per 1,000. That is a genuine, prospective signal, and it is why MRI has the strongest footing of the supplemental options. Even so, fewer interval cancers is an intermediate result, a plausible step toward fewer deaths rather than a measured mortality benefit. And it applies specifically to MRI in the extremely dense group, not to ultrasound and not to the entire "dense" population the notice covers.

The U.S. Preventive Services Task Force arrived at the same edge from the other direction. Its 2024 breast cancer screening recommendation issued an "I" statement for supplemental ultrasound or MRI, concluding that current evidence is insufficient to weigh benefits against harms, regardless of density, because no study reported health outcomes or progression to advanced cancer beyond a single round of screening. An "I" statement is not a recommendation against supplemental imaging. It is an honest label on a gap in the evidence.

How to use your notification#

Read the notice for what it accurately states: your tissue reads as dense, and supplemental imaging might catch cancers a mammogram misses. It is not proof that supplemental imaging will help you specifically, and it is not an order for a test. The reasonable next step is the one the rule itself points to. Bring the notice to a clinician who can set your density beside your full risk picture, including family history and any inherited risk, and weigh the real tradeoff: more cancers found against more false alarms and biopsies. For a woman at high overall risk, especially with extremely dense tissue, that conversation may well lead to MRI. For someone at average risk, it may lead to continued mammography and watchful reassurance.